We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04412174
Recruitment Status : Unknown
Verified May 2020 by Hebei Yanda Ludaopei Hospital.
Recruitment status was:  Not yet recruiting
First Posted : June 2, 2020
Last Update Posted : June 2, 2020
Gracell Biotechnology Ltd.
Information provided by (Responsible Party):
Hebei Yanda Ludaopei Hospital

Brief Summary:
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-NHL. The investigators plan to include 18 subjects to receive GC022F therapy.

Condition or disease Intervention/treatment Phase
B-cell Non Hodgkin Lymphoma Biological: GC022F Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
Estimated Study Start Date : June 2020
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: GC022F
The patients will receive GC022F CAR-T treatment. GC022F dosage ranges from 3×10^5 to 1×10^6 CAR+T/Kg.
Biological: GC022F
GC022F is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The dosage ranges from 3×10^5 to 1×10^6 CAR+T/Kg.

Primary Outcome Measures :
  1. Type and incidence of DLT, incidence and severity of treatment related AE, CRS and Neurotoxicity (Safety and tolerability) [ Time Frame: 2 years ]
    AE will be collected and graded according to ASTCT consensus(for Cytokine Release Syndrome, CRS and Immune Effector Cell-Associated Neurotoxicity Syndrome, ICANS) and CTCAE v5.0(for AE except CRS/ICANS)

Secondary Outcome Measures :
  1. CAR copies of GC022F in peripheral blood, bone marrow, CSF and tumor tissue (amplification and persistence) [ Time Frame: 2 years ]
    GC022F CAR copies in peripheral blood, tumor tissue, bone marrow and CSF will be measured by qPCR in 2 years.

  2. CAR cells of GC022F in peripheral blood, bone marrow and CSF (amplification and persistence) [ Time Frame: 2 years ]
    GC022F CAR cells in peripheral blood, bone marrow and CSF will be measured by FCM in 2 years.

  3. Objective response rate (ORR) (efficacy) [ Time Frame: 3 months ]
    ORR will be calculated as the percents of patients who achieved CR or PR.

  4. Duration of Response (DOR) (efficacy) [ Time Frame: 2 years ]
    DOR will be calculated as the time from the first assessment of CR or PR to the first assessment of relapse or death from any cause.

  5. Progression-Free Survival (PFS) (efficacy) [ Time Frame: 2 years ]
    PFS will be calculated as the time from CAR-T infusion to disease progression or death from any cause (whichever occurs first).

  6. Overall Survival (OS) (efficacy) [ Time Frame: 2 years ]
    OS will be calculated as the time from CAR-T infusion to death from any cause.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Aged 18-70 years;
  2. Relapsed or refractory B cell non-Hodgkin's lymphoma (B-NHL): 1) Chemotherapy-refractory disease, defined as one or more of the following: a) No response to first-line therapy (primary refractory disease, subjects who are intolerant to first-line therapy chemotherapy are excluded): i. PD as the best response to first-line therapy; ii.SD as the best response after at least 4 cycles of first-line therapy (e.g., 4 cycles of R-CHOP) with SD duration no longer than 6 months from last dose of therapy; b) No response to second or greater lines of therapy: i. PD as the best response to most recent therapy regimen; ii. SD as the best response after at least 2 cycles of last line of therapy with SD duration no longer than 6 months from last dose of therapy; c) Refractory post-ASCT(autologous stem cell transplantation): i. Disease progression or relapsed ≤12 months of ASCT (must have biopsy proven recurrence in relapsed subjects); ii. If salvage therapy is given post-ASCT, the subject must have had no response to or relapsed after the last line of therapy; d) PD or SD as the best response after previous CAR-T therapy (at least 3 months ago); 2) Subjects must have received adequate prior therapy including at a minimum: anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative, and an anthracycline containing chemotherapy regimen; for subjects with transformed FL must have received prior chemotherapy for follicular lymphoma and subsequently have chemotherapy-refractory disease after transformation to DLBCL; 3) At least 1 measurable lesion according to the Lugano Response Criteria (Cheson 2014). Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy: a) For nodular lesions, longest diameter ≥15mm, no requirement for shortest diameter; b) For extranodal lesions (lesions other than lymph node and nodular lesions, including liver and spleen), longest diameter ≥10mm, no requirement for shortest diameter;
  3. ECOG performance status ≤2 score;
  4. Life expectancy≥12 weeks;
  5. CD19 and/or CD22 positive expression demonstrated in tumor tissue;
  6. Adequate organ function defined as: 1) Creatinine clearance (as estimated by Cockcroft Gault method)>60 mL/min; for male, creatinine clearance=[ (140-age)×weight(kg)]/[0.818×creatinine (μmol/L)] ; for female, creatinine clearance =[(140-age)×weight(kg)×0.85]/[0.818×creatinine (μmol/L)]; 2) Serum ALT/AST<2.5×ULN (for subjects with liver metastases, ALT/AST≤5×ULN); 3) Total bilirubin<1.5×ULN (for subjects with Gilbert's syndrome, total bilirubin≤ 3×ULN); 4) Left ventricular ejection fraction (LVEF)>50%, no evidence of clinically significant pericardial effusion as determined by an ECHO; 5) No clinically significant pleural effusion; 6) Baseline oxygen saturation >92% on room air;
  7. Females of reproductive age must be in non-lactation period. Females of childbearing potential must have a negative hypersensitive serum pregnancy test. All subjects must use medical-approved-contraception (such as intrauterine device and contraceptive drugs) during the period of treatment and in 2 years after CAR-T infusion; males should avoid sperm donation;
  8. Venous access can be established, peripheral blood mononuclear cells (PBMC) can be collected in researcher's judgement;
  9. Agrees to sign informed consent form;
  10. Be able to make good communication with researchers, willing and able to comply with the planned visit, complete the research according to regulations.

Exclusion Criteria:

  1. Gastrointestinal involvement;
  2. Active central nervous system (CNS) involvement;
  3. Concomitant malignancy other than: cured non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ, other malignancy whose disease-free survival exceeds 5 years;
  4. Any result of the following virology tests is positive: HIV; HCV; HBsAg; or HBCAb positive with HBV DNA copies positive; TPPA;
  5. Live vaccine ≤4 weeks prior to enrollment;
  6. Autologous stem cell transplantation (ASCT) ≤6 weeks prior to enrollment, history of allogeneic hematopoietic stem cell transplantation (allo-HSCT);
  7. Presence of complication that require systemic corticosteroids or other immunosuppressive drugs therapy during the trial in researcher's judgement;
  8. CNS stereotactic radiotherapy ≤4 weeks prior to enrollment;
  9. Toxicities related to previous therapy did not relieved to ≤1 grade, except hematological toxicity and alopecia;
  10. Known life-threatening hypersensitivity to cyclophosphamide or fludarabine, or presence of other intolerant conditions, or severe allergic constitution;
  11. Presence of active autoimmune disease (including but not limited to, systemic lupus erythematosus, sjogren syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Hashimoto's thyroiditis, hypothyroidism which can be controlled by thyroid hormone replacement therapy is an exception);
  12. Major surgical operation that require general anesthesia happened ≤4 weeks prior to enrollment, or did not be fully recovered and clinically stable prior to enrollment, or be anticipated to undergo major surgical operation that require general anesthesia during the study;
  13. Usage of investigational drug ≤28 days prior to enrollment;
  14. Any unstable cardiovascular disease happened ≤6 months prior to enrollment, including but not limited to, unstable angina, myocardial infarction, heart failure (NYHA grade ≥ III grade), severe arrhythmia that require drug interference, cardiac angioplasty/coronary stent implantation/cardiac bypass surgery ≤6 months prior to enrollment;
  15. Presence of CNS disease or disease history, including epilepsy, cerebral Ischemia/bleeding, dementia, cerebellar disease, any autoimmune disease that involves CNS;
  16. Any other condition that researcher think it is inappropriate for the subject to anticipate the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04412174

Layout table for location contacts
Contact: Peihua Lu, PhD&MD +86-0316-3306393 Peihua_lu@126.com

Layout table for location information
China, Hebei
Hebei Yanda Ludaopei Hospital
Sanhe, Hebei, China, 065200
Contact: Peihua Lu, PhD&MD    +86-0316-3306393      
Sponsors and Collaborators
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.
Layout table for investigator information
Principal Investigator: Peihua Lu, PhD&MD Hebei Yanda Ludaopei Hospital
Layout table for additonal information
Responsible Party: Hebei Yanda Ludaopei Hospital
ClinicalTrials.gov Identifier: NCT04412174    
Other Study ID Numbers: PGC011
First Posted: June 2, 2020    Key Record Dates
Last Update Posted: June 2, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases